Sequenom (SQNM +1.7%) finishes higher after saying it's entered into a technology licensing and...

|By:, SA News Editor

Sequenom (SQNM +1.7%) finishes higher after saying it's entered into a technology licensing and marketing agreement with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. Under the agreement, SQNM will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France, as well as Belgium, Luxembourg and portions of the Middle East and Africa. The contract is effective immediately and active through 2018.